Objective To evaluate the risk of stroke and myocardial infarction (MI) in adult patients with systemic lupus erythematosus (SLE) through a systematic review and meta-analysis. Methods We searched ...

The same goes for people who live with autoimmune diseases such as lupus. Some foods can be very helpful in calming inflammation while other foods can trigger it and cause flare-ups. There’s a lot you ...

Background This study aimed to investigate the clinical characteristics, outcomes, and risk factors of patients with a rare but fatal manifestation of systemic lupus erythematosus (SLE), diffusive ...

Many lupus patients experience serious heart problems, ranging from heart valve disease to heart attacks, as a result of their disease activity. The following questions may help you better understand ...

Systemic lupus erythematosus (SLE), often referred to as simply “lupus” is a chronic, systemic autoimmune disease that affects many organ systems – most commonly the skin, joints, and kidneys. Due to ...

Objectives While diffuse alveolar haemorrhage (DAH) is recognised as a life-threatening complication of systemic lupus erythematosus (SLE), little is known about its risk factors and response to ...

Memorial Day is May 26 and as local residents prepare for a long holiday weekend, they will have several free events to choose from to help celebrate the nation's servicemen and women, while raising ...

Overall, 25.7% of patients with lupus nephritis demonstrated a responsive and monophasic disease course. Roughly 1 in 4 patients with lupus nephritis (LN) may follow a responsive and monophasic ...

“We are pleased to present at LUPUS 2025 the first reported Phase 1 results for a cGAS inhibitor, demonstrating that VENT-03 has the potential to become a first- and best-in-class therapy for ...

SLE flares continue to occur after ESKD in a substantial subset of patients, warranting closer monitoring. Extrarenal lupus flares continue to occur in more than one-third of patients with end-stage ...

This study is being conducted to evaluate the safety, tolerability, and ability to manufacture Descartes-08, an investigational mRNA CAR-T cell therapy, in people living with moderate to severe ...

In addition, the Company's Vice President of Clinical Development, Barbara Mittleman, M.D, is an invited speaker at the congress in the following Scientific Session: AbelZeta is a global ...